World Health Organization site
Skip Navigation Links

Note: This record shows only 21 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register.
Last refreshed on: 19 February 2015
Main ID:  NCT01238185
Date of registration: 09/11/2010
Prospective Registration: Yes
Primary sponsor: Institute of Head and Neck Studies and Education, United Kingdom
Public title: Aspirin Mouthwash in Treating Patients With Oral Leukoplakia
Scientific title: Oral Topical Cyclooxygenase Inhibitor (Aspirin) Mouthwash for Treatment of Oral Dysplasia
Date of first enrolment: February 2010
Target sample size: 40
Recruitment status: Completed
Study type:  Interventional
Study design:  Masking: Open Label, Primary Purpose: Treatment  
Phase:  Phase 1
Countries of recruitment
United Kingdom
Name:     Hisham Mehanna, MD
Affiliation:  Institute of Head and Neck Studies and Education, United Kingdom
Key inclusion & exclusion criteria


- Clinically diagnosed oral leukoplakia requiring a tissue biopsy for histological

- Attending the outpatient clinic


- Not nursing

- No known or suspected sensitivity to aspirin or other nonsteroidal anti-inflammatory

- No diagnosis of asthma or angioedema

- No contraindications, including any of the following:

- Active peptic ulceration or a history of peptic ulceration

- Hemophilia or a history of bleeding disorders

- Gout or a history of gout


- No concurrent regular use of aspirin for heart disease or other reasons

- No other concurrent nonsteroidal anti-inflammatory drugs

Age minimum: N/A
Age maximum: N/A
Gender: Both
Health Condition(s) or Problem(s) studied
Precancerous Condition
Drug: acetylsalicylic acid
Genetic: gene expression analysis
Genetic: protein expression analysis
Other: laboratory biomarker analysis
Other: questionnaire administration
Procedure: biopsy
Primary Outcome(s)
COX-1 and COX-2 mRNA as assessed by qRT-PCR [Time Frame: No]
COX-1 and COX-2 protein expression as assessed by immunohistochemistry and quantified by immunoblotting to determine whether COX inhibition in oral dysplasia tissues is actually possible by use of the mouthwash formulation [Time Frame: No]
PGE2 levels as assessed by enzyme immunosorbent assay [Time Frame: No]
Secondary Outcome(s)
Comparison of WHO histological grade and clinical size of dysplastic lesions before and after treatment and assessment of proliferating cell nuclear antigen [Time Frame: No]
Global gene response of dysplastic tissue as assessed by Affymetrix gene expression microarrays [Time Frame: No]
Protein expression as assessed by ELISA and immunohistochemistry for VEGFA [Time Frame: No]
Tolerability and possible oral and other adverse effects using a questionnaire [Time Frame: Yes]
VEGF mRNA expression as assessed by qRT-PCR [Time Frame: No]
Secondary ID(s)
Source(s) of Monetary Support
Please refer to primary and secondary sponsors
Secondary Sponsor(s)
Results available:
Date Posted:
Disclaimer: Trials posted on this search portal are not endorsed by WHO, but are provided as a service to our users. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to in this section. None of the information obtained through use of the search portal should in any way be used in clinical care without consulting a physician or licensed health professional. WHO is not responsible for the accuracy, completeness and/or use made of the content displayed for any trial record.
Copyright - World Health Organization - Version 3.6 - Version history